Markedly reduced skeletal muscle oxidative capacity with elevated circulating GDF-15 in children with cerebral palsy
Abstract Background Cerebral palsy (CP) is associated with progressive skeletal muscle weakness and reduced physical capacity, yet the contribution of mitochondrial dysfunction to these impairments remains incompletely understood. Methods We therefore evaluated skeletal muscle mitochondrial health in children with CP and typically developing (TD) children (12.9±3.4years) using a comprehensive approach integrating high-resolution respirometry, targeted protein analyses, circulating biomarkers, and plasma proteomics. Thirty-six skeletal muscle biopsies from 22 children with CP, and 15 muscle biopsies from TD children were collected during planned orthopedic surgery. Results Skeletal muscle from children with CP exhibited markedly reduced oxidative capacity (−50% in CP vs TD, p <0.001), accompanied by broad reductions in mitochondrial and substrate transport proteins suggesting reduced mitochondrial content. Despite the absence of local or systemic inflammation, circulating growth differentiation factor-15 (GDF-15), a biomarker of mitochondrial distress, was elevated in children with CP (337±53 vs 626±547pg·ml −1 for TD vs CP, p <0.05) and was highest among those with more severe motor impairments. Conclusion These findings demonstrate that previously reported reductions in skeletal muscle mitochondrial protein content in CP translate into profound impairments in mitochondrial function. Moreover, the dissociation between mitochondrial dysfunction and inflammatory signaling suggests that mitochondrial insufficiency in CP occurs independently of inflammation. Elevated circulating GDF-15 further suggests that mitochondrial dysfunction in CP may extend beyond skeletal muscle and exert systemic effects. Together, our findings identify mitochondrial insufficiency as a prominent feature of skeletal muscle pathology in CP potentially acting as a contributor to secondary health complications across the lifespan
Authors
- Johanna T. Lanner (ORCID: https://orcid.org/0000-0002-1222-9473)
- Julia Röja (ORCID: https://orcid.org/0009-0009-6829-1469)
- Linnéa Corell (ORCID: https://orcid.org/0009-0005-7489-3280)
- William Apró (ORCID: https://orcid.org/0000-0003-1942-2919)
- Oscar Horwath (ORCID: https://orcid.org/0000-0002-3500-2896)
- Evgenia Manousaki (ORCID: https://orcid.org/0000-0001-6141-4379)
- Ferdinand von Walden (ORCID: https://orcid.org/0000-0003-1134-2252)
- Eva Pontén (ORCID: https://orcid.org/0000-0001-5228-1914)
- Filip Jon Larsen (ORCID: https://orcid.org/0000-0002-1343-8656)
- Sebastian Edman (ORCID: https://orcid.org/0000-0003-2921-833X)
- Rebekah Ding Jin (ORCID: https://orcid.org/0009-0003-4464-4756)
- Baptiste Jude
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Swedish School of Sport and Health Sciences (SE)
Publication Details
- Journal
- Molecular Medicine
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1186/s10020-026-01700-4
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Karolinska Institutet